Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 10, No. 6, 382-391, June 2005; doi:10.1634/theoncologist.10-6-382
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosen, L. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosen, L. S.

VEGF-Targeted Therapy: Therapeutic Potential and Recent Advances

Lee S. Rosen

John Wayne Cancer Institute and St. John’s Health Center, Santa Monica, California, USA

Correspondence: Correspondence: Lee S. Rosen, M.D., 2020 Santa Monica Boulevard, Suite 510, Santa Monica, California 90404, USA. Telephone: 310-633-8400; Fax: 310-633-8419; e-mail: lrosen{at}premiereoncology.com

After over 30 years of theorizing, the use of angiogenesis inhibitors as anticancer therapy has finally moved from the realm of research to reality. Normal adult vasculature is generally quiescent in nature, with endothelial cells dividing approximately every 10 years. In contrast, the growth of tumors requires constant vascular growth and remodeling in order for solid tumors to grow beyond 1–2 mm3 in size. Vascular endothelial growth factor (VEGF) and its receptors are key regulators of the process of angiogenesis, which makes them attractive therapeutic targets. A multitude of VEGF-targeted inhibitory agents are currently being investigated for the treatment of cancer. This review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast, lung, and colorectal cancers.

Key Words. Angiogenesis • Lung cancer • VEGF • Vascular endothelial growth factor • Colorectal cancer • Breast cancer • Bevacizumab • Vatalanib • PTK787




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
B. Besse, S. F. Lasserre, P. Compton, J. Huang, S. Augustus, and U.-P. Rohr
Bevacizumab Safety in Patients with Central Nervous System Metastases
Clin. Cancer Res., January 1, 2010; 16(1): 269 - 278.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. DePrimo, et al.
Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
J. Clin. Oncol., April 10, 2008; 26(11): 1810 - 1816.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
C.R. Dass, T.M.N. Tran, and P.F.M. Choong
Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics
Journal of Dental Research, October 1, 2007; 86(10): 927 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. G. Duda
Antiangiogenesis and drug delivery to tumors: bench to bedside and back.
Cancer Res., April 15, 2006; 66(8): 3967 - 3970.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2005 by AlphaMed Press.
Advertisement